血浆外泌体中神经颗粒素对阿尔茨海默病患者脑结构和功能的影响研究
摘要
茨海默病（AD）[1]。除了淀粉样蛋白和 tau 蛋白外，突触功能障碍是 AD 重要的病理生理改变，神经颗粒素参与调节突触
可塑性，但目前血浆神经颗粒素在 AD 早期的变化及其与认知和神经退行性变之间的关系尚未明确。本项目拟通过比较早
期 AD 患者与正常对照血浆神经源性外泌体中的神经颗粒素，明确其随 AD 进展的改变模式及诊断效能进一步分析神经颗
粒素含量与认知下降和脑结构及功能之间的相关性。将通过本项目明确血浆神经颗粒素在 AD 早期的改变模式及其对 AD
病程的影响机制，阐明神经颗粒素在 AD 患者认知、脑结构和功能改变中所起到的作用，从而为 AD 早期诊断和认知下降
预测提供新的标记物。
关键词
全文:
PDF参考
[1]1990—2019 年中国偏头痛发病趋势及其年龄 - 时期 -
队列分析 [J]. 徐若愚 ; 王家琛 ; 林玥彤 ; 冯善刚 ; 张建华 . 中
国循证医学杂志 ,2024(06)
[2] 宋皓 , 李玉萍 , 王松华 , 等 . 阿尔茨海默症突触功能
障碍研究进展 [J]. 生命科学 ,2018,30(01):20-26.DOI:10.13376/
j.cbls/2018003.
[3]Willemse EAJ, Sieben A, Somers C, Vermeiren Y, De
Roeck N, Timmers M, Van Broeckhoven C, De Vil B, Cras P, De
Deyn PP, Martin JJ, Teunissen CE, Engelborghs S, Bjerke M.
Neurogranin as biomarker in CSF is non-specific to Alzheimer’s
disease dementia. Neurobiol Aging. 2021 Dec;108:99-109.
[4]Tarawneh R, D’Angelo G, Crimmins D, Herries E,
Griest T, Fagan AM, Zipfel GJ, Ladenson JH, Morris JC, Holtzman
DM. Diagnostic and Prognostic Utility of the Synaptic Marker
Neurogranin in Alzheimer Disease. JAMA Neurol 2016, 73(5):
561-571.
[5]Yoong SQ, Lu J, Xing H, Gyanwali B, Tan YQ, Wu XV.
The prognostic utility of CSF neurogranin in predicting future
cognitive decline in the Alzheimer’s disease continuum: A
systematic review and meta-analysis with narrative synthesis.
Ageing Res Rev. 2021 Dec;72:101491..
[6]Goetzl EJ, Kapogiannis D, Schwartz JB, Lobach IV,
Goetzl L, Abner EL, Jicha GA, Karydas AM, Boxer A, Miller
BL. Decreased synaptic proteins in neuronal exosomes of
frontotemporal dementia and Alzheimer’s disease. FASEB J
2016, 30(12): 4141-4148.
[7]Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q.
Alzheimer’s Disease: Epidemiology and Clinical Progression.
Neurol Ther. 2022 Jun;11(2):553-569.
[8]Lista S, Toschi N, Baldacci F, Zetterberg H, Blennow K,
Kilimann I, Teipel SJ, Cavedo E, Dos Santos AM, Epelbaum S,
Lamari F, Dubois B, Nistico R, Floris R, Garaci F, Hampel H,
Alzheimer Precision Medicine I. Cerebrospinal Fluid Neurogranin
as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional
Study. J Alzheimers Dis 2017, 59(4): 1327-1334.
[9]Portelius E, Zetterberg H, Skillback T, Tornqvist
U, Andreasson U, Trojanowski JQ, Weiner MW, Shaw LM,
Mattsson N, Blennow K, Alzheimer’s Disease Neuroimaging
I. Cerebrospinal fluid neurogranin: relation to cognition and
neurodegeneration in Alzheimer’s disease. Brain 2015, 138(Pt
11): 3373-3385.
[10]Kester MI, Teunissen CE, Crimmins DL, Herries EM,
Ladenson JH, Scheltens P, van der Flier WM, Morris JC, Holtzman
DM, Fagan AM. Neurogranin as a Cerebrospinal Fluid Biomarker
for Synaptic Loss in Symptomatic Alzheimer Disease. JAMA
Neurol 2015, 72(11): 1275-1280.
[11]Headley A, De Leon-Benedetti A, Dong C, Levin B,
Loewenstein D, Camargo C, Rundek T, Zetterberg H, Blennow
K, Wright CB, Sun X, Alzheimer’s Disease Neuroimaging I.
Neurogranin as a predictor of memory and executive function
decline in MCI patients. Neurology 2018, 90(10): e887-e895.
[12]Jurasova V, Andel R, Katonova A, Veverova K,
Zuntychova T, Horakova H, Vyhnalek M, Kolarova T, Matoska
V, Blennow K, Hort J. CSF neurogranin levels as a biomarker
in Alzheimer’s disease and frontotemporal lobar degeneration:
a cross-sectional analysis. Alzheimers Res Ther. 2024 Sep
6;16(1):199.
[13]Sadeghi M, Azargoonjahromi A, Nasiri H, Yaghoobi A,
Sadeghi M, Chavoshi SS, Baghaeikia S, Mahzari N, Valipour A,
Razeghi Oskouei R, Shahkarami F, Amiri F, Mayeli M. Altered
brain connectivity in mild cognitive impairment is linked to
elevated tau and phosphorylated tau, but not to GAP-43 and
Amyloid-β measurements: a resting-state fMRI study. Mol
Brain. 2024 Aug 30;17(1):60.
[14]Sanfilippo C, Forlenza O, Zetterberg H, Blennow K.
Increased neurogranin concentrations in cerebrospinal fluid of
Alzheimer’s disease and in mild cognitive impairment due to
AD. J Neural Transm (Vienna) 2016, 123(12): 1443-1447.
[15]Hellwig K, Kvartsberg H, Portelius E, Andreasson U,
Oberstein TJ, Lewczuk P, Blennow K, Kornhuber J, Maler JM,
Zetterberg H, Spitzer P. Neurogranin and YKL-40: independent
markers of synaptic degeneration and neuroinflammation in
Alzheimer’s disease. Alzheimers Res Ther 2015, 7: 74.
[16]Wellington H, Paterson RW, Portelius E, Tornqvist U,
Magdalinou N, Fox NC, Blennow K, Schott JM, Zetterberg H.
Increased CSF neurogranin concentration is specific to Alzheimer
disease. Neurology 2016, 86(9): 829-835.
[17] 林璐 , 马辛 , 王刚 , 等 . 中国阿尔茨海默病早期预防
指南（2024）[J]. 阿尔茨海默病及相关病杂志 ,2024,7(03):168-
175.
[18]Su L, Hayes L, Soteriades S, Williams G, Brain SAE,
Firbank MJ, Longoni G, Arnold RJ, Rowe JB, O’Brien JT.
Hippocampal Stratum Radiatum, Lacunosum, and Moleculare
Sparing in Mild Cognitive Impairment. J Alzheimers Dis 2018,
61(1): 415-424.
[19]Wang X, Yu Y, Zhao W, Li Q, Li X, Li S, Yin C, Han Y.
Altered Whole-Brain Structural Covariance of the Hippocampal
Subfields in Subcortical Vascular Mild Cognitive Impairment and
Amnestic Mild Cognitive Impairment Patients. Front Neurol 2018,
9: 342.
[20]Zhao W, Wang X, Yin C, He M, Li S, Han Y.
Trajectories of The Hippocampal Subfields Atrophy in the
Alzheimer’s Disease: A Structural Imaging Study. Frontiers in
Neuroinformatics， 2019.
(5 摘要 Views, 5 PDF Downloads)
Refbacks
- 当前没有refback。